- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cinclus Pharma Holding AB (CINPHA)
Cinclus Pharma Holding AB stock price live, this page displays ST CINPHA stock exchange data. View the CINPHA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cinclus Pharma Holding AB real time stock price chart below.
What Is the Cinclus Pharma Holding AB Stock Price Today?
The Cinclus Pharma Holding AB stock price today is 11.58.
What Is the Stock Symbol for Cinclus Pharma Holding AB?
The stock symbol for Cinclus Pharma Holding AB is "CINPHA."
What Stock Exchange Does Cinclus Pharma Holding AB Trade On?
Cinclus Pharma Holding AB is listed and trades on the Stockholm stock exchange.
Is Cinclus Pharma Holding AB a Good Stock to Buy?
Determining whether Cinclus Pharma Holding AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CINPHA quote. (ISIN: SE0020388577)
What Is the Cinclus Pharma Holding AB Stock Price Today?
The Cinclus Pharma Holding AB stock price today is 11.58.
What Is the Stock Symbol for Cinclus Pharma Holding AB?
The stock symbol for Cinclus Pharma Holding AB is "CINPHA."
What Stock Exchange Does Cinclus Pharma Holding AB Trade On?
Cinclus Pharma Holding AB is listed and trades on the Stockholm stock exchange.
Is Cinclus Pharma Holding AB a Good Stock to Buy?
Determining whether Cinclus Pharma Holding AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CINPHA quote. (ISIN: SE0020388577)
Stockholm
Currency in SEK
11.58
+0.16(+1.40%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.48
11.78
52 wk Range
10.48
19.64
CINPHA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.4811.78
52 wk Range
10.4819.64
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CINPHA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
45.25
Upside
+290.76%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 45.25
(+290.76% Upside)
Cinclus Pharma Holding AB Earnings Call Summary for Q3/2026
- Cinclus Pharma reported Q3 2026 net loss of SEK 114M with cash at SEK 281M, sufficient to fund operations into Q4 2027 per management.
- Company completed all patient visits in Phase III HEEALING1 trial; top-line results expected Q4 2026, representing key near-term catalyst.
- R&D expenses rose to 94% of operating costs vs. 88% average, reflecting late-stage trial execution; revenue minimal at SEK 2M from licensing.
- Stock fell 2.8% to $11.82, trading near 52-week low of $10.48, suggesting investor caution ahead of pivotal trial readout.
- CEO highlighted linaprazan glurate's differentiation as next-gen PCAB; HEEALING2 trial planned for 2027, U.S. commercialization strategy pending.
Last Updated: 11/11/2026, 09:48 PM
Read Full TranscriptEarnings
Latest Release
Nov 12, 2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
Compare CINPHA to Peers and Sector
Metrics to compare | CINPHA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCINPHAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.6x | −118.1x | −0.2x | |
PEG Ratio | 0.02 | −1.53 | 0.00 | |
Price/Book | 8.3x | 9.0x | 2.6x | |
Price / LTM Sales | 20.0x | 6.5x | 2.8x | |
Upside (Analyst Target) | 288.6% | 0.0% | 63.4% | |
Fair Value Upside | Unlock | 23.0% | 9.5% | Unlock |
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori. Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Cinclus Pharma Holding AB (CINPHA) Stock Price Today?
The Cinclus Pharma Holding AB stock price today is 11.58 SEK.
What Stock Exchange Does Cinclus Pharma Holding AB Trade On?
Cinclus Pharma Holding AB is listed and trades on the Stockholm Stock Exchange.
What Is the Stock Symbol for Cinclus Pharma Holding AB?
The stock symbol for Cinclus Pharma Holding AB is "CINPHA."
What Is the Cinclus Pharma Holding AB Market Cap?
As of today, Cinclus Pharma Holding AB market cap is 531.46M SEK.
What Is Cinclus Pharma Holding AB's Earnings Per Share (TTM)?
The Cinclus Pharma Holding AB EPS (TTM) is -7.35.
From a Technical Analysis Perspective, Is CINPHA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Cinclus Pharma Holding AB Stock Split?
Cinclus Pharma Holding AB has split 0 times.
How Many Employees Does Cinclus Pharma Holding AB Have?
Cinclus Pharma Holding AB has 17 employees.
What is the current trading status of Cinclus Pharma Holding AB (CINPHA)?
As of Nov 13, 2026, Cinclus Pharma Holding AB (CINPHA) is trading at a price of 11.58 SEK, with a previous close of 11.42 SEK. The stock has fluctuated within a day range of 11.48 SEK to 11.78 SEK, while its 52-week range spans from 10.48 SEK to 19.64 SEK.
What Is Cinclus Pharma Holding AB (CINPHA) Price Target According to Analysts?
The average 12-month price target for Cinclus Pharma Holding AB is 45.25 SEK, with a high estimate of 70 SEK and a low estimate of 25 SEK. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +290.76% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.